ImetelChat

AML: Imetelstat in xenografts derived from AML patients
http://www.geron.com/PDFs/Bruedigam-Ime ... H-2016.pdf
(Abstract #578)

MF: An analysis of treatment patterns and outcomes of patients with MF
http://www.geron.com/PDFs/Mehra-JJ-MF-ASH-2016.pdf
(Abstract #4769)

ET: Telomere length dynamics in ET patients treated with imetelstat
http://www.geron.com/PDFs/Haubitz-Imete ... H-2016.pdf
(Abstract #1938)

CML: Imetelstat in preclinical models of blast crisis CML
http://www.geron.com/PDFs/Ma-Imetelstat-ASH-2016.pdf
(Abstract #3065)

Geron press release:
Menlo Park, Dec. 06, 2016 (GLOBE NEWSWIRE)
Geron Corporation (GERN) today announced four presentations of exploratory preclinical and clinical data related to the imetelstat program at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, California from December 3-6, 2016. The presentations are available on Geron’s website at www.geron.com/presentations.

“The imetelstat data presented at ASH this year indicate the potential application of imetelstat in multiple myeloid malignancies,” said John A. Scarlett, M.D., Geron’s President and Chief Executive Officer. “These presentations reflect the ongoing work by academic scientists, clinical investigators and our colleagues at Janssen to advance the imetelstat program, and support the clinical trials being conducted by Janssen in patients with myelofibrosis and myelodysplastic syndromes, who are in need of new treatment options.”

Thanks for posting these Fish. Sometimes additional data is provided during the actual presentation, but I didn't see any. So far all I can see is essentially the same message provided previously when the abstracts were released in November. No new bombshells but some implications: 1. I think we can expect an AML phase I and maybe a CML study too. Timing is uncertain as always but Scarlett did say they expected to do something before the end of 2016, that leave three weeks and I would be surprised if he makes good on the very old statement (which was not reiterated for about a year). Sounds in retrospect like a Trumpian promise! But I still think they have set the table for something. 2. They are highlighting the longevity issue with current approved therapies and plan a major contrast when the next data set is released in Q2. That could mean as early as April 1st or as late as June 30th. Considering that three months from the last Sunday surprise announcement would allow data analysis well before April, I suspect they plan to include a separate assessment of the 4.7 patients who will have received 9.4 dose for several months also. So when the announcement comes the data from the Mayo pilot trial, the Janssen 4.7 to 9.4 dose group, the original 9.4 group that did not receive a lower dose and the MDS phase II/III group will probably all be presented in "one swell foop" . By then we should know about AML/CML studies too. Champagne or cyanide then... bp

Thanks, bio. I share your observations. Ad 1: the AML trials is even part of the collaboration agreement and was indeed set for the end of 2016. They must have seen some interesting data already by then. Until now, further clinical studies confirm that AML is a valid target. Maybe we will get a surpise before 31 December...